Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up

Journal of the American Society of Nephrology

Volumn 28, Issue 1, 2017, Pages 348-358

  Dahan, Karine ^a   Debiec, Hanna ^b,c   Plaisier, Emmanuelle ^a,b,c   Cachanado, Marine ^d   Rousseau, Alexandra ^d   Wakselman, Laura ^d   Michel, Pierre Antoine ^a   Mihout, Fabrice ^a   Dussol, Bertrand ^e   Matignon, Marie ^f   Mousson, Christiane ^g   Simon, Tabassome ^d   Ronco, Pierre ^a,b,c  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e TIMONE HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CD19 ANTIGEN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; SERUM ALBUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ACUTE KIDNEY FAILURE; ADULT; ANTIBODY TITER; ARTICLE; ASTHMA; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICAL LIMB ISCHEMIA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FEVER; FOLLOW UP; HEART INFARCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEMBRANOUS GLOMERULONEPHRITIS; MESENTERIC ISCHEMIA; MIDDLE AGED; MULTICENTER STUDY; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PLEURA EFFUSION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATITIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; CLINICAL TRIAL; GLOMERULONEPHRITIS, MEMBRANOUS; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85021849895     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016040449     Document Type: Article

References (31)

1. Ponticelli C, Glassock RJ: Glomerular diseases: Membranous nephropathy-a modern view. Clin J Am Soc Nephrol 9: 609-616, 2014
2. Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
3. Hofstra JM, Fervenza FC, Wetzels JF: Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 9: 443-458, 2013
4. Cravedi P, Remuzzi G, Ruggenenti P: Rituximab in primary membranous nephropathy: First-line therapy, why not?Nephron Clin Pract 128: 261-269, 2014
5. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
6. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las EnfermedadesGlomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
7. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sasdelli M, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989
8. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
9. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
10. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O'Donoghue D, Boulton-Jones M, Mathieson PW: Immunosuppression for progressivemembranous nephropathy: A UK randomised controlled trial. Lancet 381: 744-751, 2013
11. Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N, Perna A: Immunosuppression for membranous nephropathy: A systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 8: 787-796, 2013
12. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S; Canadian Glomerulonephritis Study Group: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47: 1130-1135, 1995
13. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
14. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71: 924-930, 2007
15. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 186-197, 2012
16. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF: Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 25: 150-158, 2014
17. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
18. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008
19. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH: Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 4: 734-744, 2009
20. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 5: 2188-2198, 2010
21. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416-1425, 2012
22. Beck LHJr., Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti- PLA2R autoantibodies predicts response inmembranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
23. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G: Antiphospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26: 2545-2558, 2015
24. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937, 2007
25. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
26. Wagner MC, Campos-Bilderback SB, Chowdhury M, Flores B, Lai X, Myslinski J, Pandit S, Sandoval RM, Wean SE, Wei Y, Satlin LM, Wiggins RC, Witzmann FA, Molitoris BA: Proximal tubules have the capacity to regulate uptake of albumin. J Am Soc Nephrol 27: 482-494, 2016
27. Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G: Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107: 586-592, 2003
28. Du Y, Li J, He F, Lv Y, Liu W, Wu P, Huang J, Wei S, Gao H: The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One 9: e104936, 2014
29. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl JMed 371: 2277-2287, 2014
30. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26: 2526-2532, 2011
31. Debiec H, Ronco P: PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl JMed 364: 689-690, 2011